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Identification of two distinct types of adrenotropic re-
ceptors, alpha and beta, by Raymond Ahlquist provided
the scientific basis that enabled the development of drugs
to selectively block adrenoceptor function. These phar-
" There are two distinct types of adrenotrop ic recep tors . . . the
alpha . . . is associated with most of the excitatory funct ions
. . . the beta is assoc iated with most of the inhibitory functions
.. . and one excitatory function (myocardial stimulation)" ( I ).
The recent death of Raymond Ahlquist , PhD . Charbonn ier
Professor of Pharmacology at the Medical College of Geor-
gia and originator of the theo ry of alpha- and beta-adrenergic
recept ors , recall s once again the interdependent relati ons
between basic scientific resea rch and clinical medicine . As
stated so well by Dr. Julius Cornroe , " . .. cruci al discov-
eries . essent ial to later medical miracles . were often made
by those not directly concerned with diagno sing or curing
or preventing disease. and . . . the work of many . . was
judged to be impractical. impossible . irrelevant or absurd
at the time of discovery" (2).
Ahlqu ist's neurophysiologic concept of alpha- and beta-
adrenoceptors initially served only to facilitate the under-
standing of responses of the sympathetic nervous system to
stimulation, but shortly there after became the basis for spe-
cific pharmacotherapy. Drugs were soo n found that specif-
ically stimula ted each type of rece ptor, and other substances
were subsequently ident ified that se lective ly blocked alpha-
and beta-receptor function . For exa mple. beta-receptor
blockade ef fective ly inhibits the influence of sympathetic
neurotransmitters on the heart . with a result ant beneficial
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macotherapeutic advances have improved the care of
patients with coronary and hypertensive cardiovascular
disease.
effect in patient s with ang ina pector is, sys temic arterial hy-
pertensio n. card iac tachyarrhythmias . and so forth.
As recentl y as the 1940s . the Cannon and Rosenblueth
(3) concept of two adre nergic mediator substances dom i-
nated the thinking of research scientists about the function
of the sympathetic nervous system. They postulat ed the
presence of an adrenergic receptor . a tissue component that
reacted with epinephr ine from the nerve ending to form
sympathin. Epinephrine was bel ieved to exis t in two form s;
sympat hin E was co nsidered excitatory and sympathin I an
inhibitory mediator.
Catecholamine Studies
Dr. Raymond Ahlquist . a young faculty member in the
Dep artment of Pharmacology at the Medical College of
Georgia. was intrigued by the paradoxic effects of cate -
cho lamine administration. which produc ed both excitatory
and inhibitory responses in many organ systems . The hy-
potensive response produ ced by some sympathomimetic
amines was genera lly considered to result from a depressor
effect of these dru gs on the myocardium; Ahlqu ist believed
that this depre ssor response was due to sympathomimetic-
amine-induced per ipheral vasodi lation . His study of the dif-
fer ing responses to a series of sympathomimetic amines was
encouraged by Profe ssor R. A. Woodbury. Chairman of the
Department of Pharm acology at Augusta. because of the
latter ' s interes t in sympathomimetic relaxation of the human
uteru s to treat dysmenorrh ea. Adre naline . which relaxed the
uteru s in vitro. co uld not be used in pat ients because of its
ca rdiovasc ular stimulato ry effects .
Ahlqui st performed det ailed eva luations of five cate-
chola rnines: norepinephrine . rneth ylnorepinephrine, isopro-
terenol. cobefrine and epin ephrine; he showed that the rel-
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ative order of vasoconstrictor potency demonstrated for these
compounds (and for their effect on uterine contraction, pu-
pillary dilation and inhibition of intestinal motility) did not
parallel their order of efficacy in vasodilation, myocardial
stimulation and uterine inhibition. Epinephrine had the greatest
potency and isoproterenol the least for the vasoconstrictor
responses; the potency of isoproterenol was greatest and that
of epinephrine the least for the other set of responses that
included vasodilation and cardiac stimulation (I).
Concept of Two Types of
Adrenotropic Receptors
In the paper cited earlier, Ahlquist proposed the presence
of two types of adrenotropic receptors, which he designated
as alpha and beta, and postulated that there was only one
sympathetic adrenergic mediator, epinephrine, for both the
alpha- and the beta-receptors. Sympathomimetic amine
stimulation of alpha-receptors was hypothesized to produce
vasoconstriction, with vasodilation resulting when beta-re-
ceptors were stimulated by sympathomimetic amines; car-
diac stimulation was considered a beta effect, because the
relative potency order of the various amines as myocardial
stimulants was the same as for their vasodilator actions. He
challenged the conclusions of Cannon and Rosenblueth (3)
in that no known sympathomimetic amine fulfilled the re-
quirements for either sympathin E or sympathin I. His paper
had been submitted earlier to the Journal of Pharmacology
and Experimental Therapeutics, but was rejected as not
being consistent with the accepted principles of physiology.
The new theory, however, generated neither much interest
nor significant controversy and, for a number of years, had
primarily an educational value, simplifying the teaching of
sympathetic nervous system function to medical and grad-
uate students. The concept of two fundamental types of
adrenotropic receptors appeared more reasonable than that
of two adrenergic mediators. Little attention was focused
on Ahlquist's suggestion that the concept of alpha- and beta-
adrenotropic receptors "should be useful when studying the
various actions of epinephrine, the actions and interactions
of sympathomimetic agents, and the effects of sympathetic
nerve stimulation" (l).
Demonstration of Receptor-Specific
Blocking Agents
It was not until 10 years later that Ahlquist's hypothesis
was validated by the demonstration of receptor-specific
blocking agents. In 1958, Powell and Slater (4) at the Lilly
Research Laboratories and Moran and Perkins (5) at the
Emory University School of Medicine, respectively, showed
that dichlorisoprenaline (DCI) selectively blocked sympa-
thetic inhibitory effects on the blood vessels, uterus and
Figure I. Raymond Ahlquist, PhD.
bronchi and sympathetic stimulation of the heart. Moran
and Perkins' (5) designation of the term "beta adrenore-
ceptor blocking agent" for dichlorisoprenaline (DCI) ini-
tiated the current era of the therapeutic possibilities afforded
by the application of selective adrenoceptor blockade.
During 1976 to 77, Ahlquist (6) reviewed the current
state of alpha- and beta-adrenergic drugs, bemoaning the
limited number of drugs available for clinical use in the
United States, and predicting more extensive application of
these compounds. However, in discussing the existence of
two beta-receptors, he suggested that "variable receptor
selectivity may have more laboratory interest than clinical
application. "
Current Status of Beta-Receptor
Blocking Agents
Today both selective and nonselective beta-receptor
blocking agents, with and without intrinsic sympathomi-
metic activity, are in widespread clinical use. Beta-adren-
ergic blocking agents, because of their competitive inhibi-
tion of the effects of catecholamines on beta-receptors, are
effective antianginal agents; they reduce myocardial oxygen
demand by decreasing the heart rate, cardiac output, blood
pressure and myocardial contractility, both at rest and with
exercise. Beta-adrenergic blockade also helps control hy-
pertension, in part by decreasing cardiac output; inhibition
of renin release and a specific central nervous system effect
are also postulated. The prevention or control, or both, of
cardiac tachyarrhythmias by beta-receptor blockade relates
to combinations of the decrease in sinus rate and the slowing
of atrial and atrioventricular (AV) conduction, and the de-
crease in the spontaneous rate of depolarization of ectopic
pacemakers. Recent data suggest that improved survival of
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patients after myocardial infarction appears related, at least
in part, to blockade of the beta-receptor (7-9); whether this
will provide a clue to the pathogenesis of coronary death
remains to be determined.
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